Further, these data are supported by studies demonstrating that while CCS1477 inactivates MYC in prostatic carcinoma5, other tumors such as acute myeloid leukemia and multiple myeloma have distinct oncogenes affected by CCS1477 treatment37. The gene discussed is MYC; the disease is plasma cell myeloma.